1u4d › Citations

Crystal structures of the phosphorylated and unphosphorylated kinase domains of the Cdc42-associated tyrosine kinase ACK1.

Lougheed JC, Chen RH, Mak P, Stout TJ
J Biol Chem 279 44039-45 (2004)
Related entries: 1u46, 1u54

Cited: 44 times
EuropePMC logo PMID: 15308621

Abstract

ACK1 is a multidomain non-receptor tyrosine kinase that is an effector of the Cdc42 GTPase. Members of the ACK family have a unique domain ordering and are the only tyrosine kinases known to interact with Cdc42. In contrast with many protein kinases, ACK1 has only a modest increase in activity upon phosphorylation. We have solved the crystal structures of the human ACK1 kinase domain in both the unphosphorylated and phosphorylated states. Comparison of these structures reveals that ACK1 adopts an activated conformation independent of phosphorylation. Furthermore, the unphosphorylated activation loop is structured, and its conformation resembles that seen in activated tyrosine kinases. In addition to the apo structure, complexes are also presented with a non-hydrolyzable nucleotide analog (adenosine 5'-(beta,gamma-methylenetriphosphate)) and with the natural product debromohymenialdisine, a general inhibitor of many protein kinases. Analysis of these structures reveals a typical kinase fold, a pre-organization into the activated conformation, and an unusual substrate-binding cleft.

Reviews - 1u4d mentioned but not cited (1)

  1. Domain Architecture of the Nonreceptor Tyrosine Kinase Ack1. Kan Y, Paung Y, Seeliger MA, Miller WT. Cells 12 900 (2023)

Articles - 1u4d mentioned but not cited (12)

  1. Variability in docking success rates due to dataset preparation. Corbeil CR, Williams CI, Labute P. J Comput Aided Mol Des 26 775-786 (2012)
  2. Automated docking screens: a feasibility study. Irwin JJ, Shoichet BK, Mysinger MM, Huang N, Colizzi F, Wassam P, Cao Y. J Med Chem 52 5712-5720 (2009)
  3. Frog2: Efficient 3D conformation ensemble generator for small compounds. Miteva MA, Guyon F, Tufféry P. Nucleic Acids Res 38 W622-7 (2010)
  4. BSP-SLIM: a blind low-resolution ligand-protein docking approach using predicted protein structures. Lee HS, Zhang Y. Proteins 80 93-110 (2012)
  5. Efficient consideration of coordinated water molecules improves computational protein-protein and protein-ligand docking discrimination. Pavlovicz RE, Park H, DiMaio F. PLoS Comput Biol 16 e1008103 (2020)
  6. Automating crystallographic structure solution and refinement of protein-ligand complexes. Echols N, Moriarty NW, Klei HE, Afonine PV, Bunkóczi G, Headd JJ, McCoy AJ, Oeffner RD, Read RJ, Terwilliger TC, Adams PD. Acta Crystallogr D Biol Crystallogr 70 144-154 (2014)
  7. Ack1: activation and regulation by allostery. Gajiwala KS, Maegley K, Ferre R, He YA, Yu X. PLoS One 8 e53994 (2013)
  8. High-throughput quantum-mechanics/molecular-mechanics (ONIOM) macromolecular crystallographic refinement with PHENIX/DivCon: the impact of mixed Hamiltonian methods on ligand and protein structure. Borbulevych O, Martin RI, Westerhoff LM. Acta Crystallogr D Struct Biol 74 1063-1077 (2018)
  9. An aggregate analysis of many predicted structures to reduce errors in protein structure comparison caused by conformational flexibility. Godshall BG, Tang Y, Yang W, Chen BY. BMC Struct Biol 13 Suppl 1 S10 (2013)
  10. Chlorinated benzothiadiazines inhibit angiogenesis through suppression of VEGFR2 phosphorylation. Huwaimel BI, Jonnalagadda S, Jonnalagadda S, Zahra FT, Nocentini A, Supuran CT, Mikelis CM, Trippier PC. Bioorg Med Chem 67 116805 (2022)
  11. A multilayer dynamic perturbation analysis method for predicting ligand-protein interactions. Gu L, Li B, Ming D. BMC Bioinformatics 23 456 (2022)
  12. Identification of Activated Cdc42-Associated Kinase Inhibitors as Potential Anticancer Agents Using Pharmacoinformatic Approaches. Kumar V, Kumar R, Parate S, Danishuddin, Lee G, Kwon M, Jeong SH, Ro HS, Lee KW, Kim SW. Biomolecules 13 217 (2023)


Reviews citing this publication (6)

  1. Shepherding AKT and androgen receptor by Ack1 tyrosine kinase. Mahajan K, Mahajan NP. J Cell Physiol 224 327-333 (2010)
  2. Mechanisms of RET signaling in cancer: current and future implications for targeted therapy. Plaza-Menacho I, Mologni L, McDonald NQ. Cell Signal 26 1743-1752 (2014)
  3. ACK1 tyrosine kinase: targeted inhibition to block cancer cell proliferation. Mahajan K, Mahajan NP. Cancer Lett 338 185-192 (2013)
  4. Structure and function of RET in multiple endocrine neoplasia type 2. Plaza-Menacho I. Endocr Relat Cancer 25 T79-T90 (2018)
  5. Research Progress of the Functional Role of ACK1 in Breast Cancer. Liu X, Wang X, Li L, Han B. Biomed Res Int 2019 1018034 (2019)
  6. ACKnowledging the role of the Activated-Cdc42 associated kinase (ACK) in regulating protein stability in cancer. Hodder S, Fox M, Binti Ahmad Mokhtar AM, Mott HR, Owen D. Small GTPases 14 14-25 (2023)

Articles citing this publication (25)

  1. Structure and chemical inhibition of the RET tyrosine kinase domain. Knowles PP, Murray-Rust J, Kjaer S, Scott RP, Hanrahan S, Santoro M, Ibáñez CF, McDonald NQ. J Biol Chem 281 33577-33587 (2006)
  2. Trans-activation of the DNA-damage signalling protein kinase Chk2 by T-loop exchange. Oliver AW, Paul A, Boxall KJ, Barrie SE, Aherne GW, Garrett MD, Mittnacht S, Pearl LH. EMBO J 25 3179-3190 (2006)
  3. Crystal structures of IRAK-4 kinase in complex with inhibitors: a serine/threonine kinase with tyrosine as a gatekeeper. Wang Z, Liu J, Sudom A, Ayres M, Li S, Wesche H, Powers JP, Walker NP. Structure 14 1835-1844 (2006)
  4. High-throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors. Miduturu CV, Deng X, Kwiatkowski N, Yang W, Brault L, Filippakopoulos P, Chung E, Yang Q, Schwaller J, Knapp S, King RW, Lee JD, Herrgard S, Zarrinkar P, Gray NS. Chem Biol 18 868-879 (2011)
  5. Down-regulation of active ACK1 is mediated by association with the E3 ubiquitin ligase Nedd4-2. Chan W, Tian R, Lee YF, Sit ST, Lim L, Manser E. J Biol Chem 284 8185-8194 (2009)
  6. Conserved tyrosine kinase promotes the import of silencing RNA into Caenorhabditis elegans cells. Jose AM, Kim YA, Leal-Ekman S, Hunter CP. Proc Natl Acad Sci U S A 109 14520-14525 (2012)
  7. Oncogenic RET kinase domain mutations perturb the autophosphorylation trajectory by enhancing substrate presentation in trans. Plaza-Menacho I, Barnouin K, Goodman K, Martínez-Torres RJ, Borg A, Murray-Rust J, Mouilleron S, Knowles P, McDonald NQ. Mol Cell 53 738-751 (2014)
  8. Conservation, variability and the modeling of active protein kinases. Knight JD, Qian B, Baker D, Kothary R. PLoS One 2 e982 (2007)
  9. Cancer-associated mutations activate the nonreceptor tyrosine kinase Ack1. Prieto-Echagüe V, Gucwa A, Craddock BP, Brown DA, Miller WT. J Biol Chem 285 10605-10615 (2010)
  10. The human kinome and kinase inhibition. Duong-Ly KC, Peterson JR. Curr Protoc Pharmacol Chapter 2 Unit2.9 (2013)
  11. Constitutive activated Cdc42-associated kinase (Ack) phosphorylation at arrested endocytic clathrin-coated pits of cells that lack dynamin. Shen H, Ferguson SM, Dephoure N, Park R, Yang Y, Volpicelli-Daley L, Gygi S, Schlessinger J, De Camilli P. Mol Biol Cell 22 493-502 (2011)
  12. Cytoplasmic ACK1 interaction with multiple receptor tyrosine kinases is mediated by Grb2: an analysis of ACK1 effects on Axl signaling. Pao-Chun L, Chan PM, Chan W, Manser E. J Biol Chem 284 34954-34963 (2009)
  13. Regulation of ack-family nonreceptor tyrosine kinases. Prieto-Echagüe V, Miller WT. J Signal Transduct 2011 742372 (2011)
  14. Small-molecule inhibitors binding to protein kinases. Part I: exceptions from the traditional pharmacophore approach of type I inhibition. Backes A, Zech B, Felber B, Klebl B, Müller G. Expert Opin Drug Discov 3 1409-1425 (2008)
  15. RET Functions as a Dual-Specificity Kinase that Requires Allosteric Inputs from Juxtamembrane Elements. Plaza-Menacho I, Barnouin K, Barry R, Borg A, Orme M, Chauhan R, Mouilleron S, Martínez-Torres RJ, Meier P, McDonald NQ. Cell Rep 17 3319-3332 (2016)
  16. The Cdc42-associated kinase ACK1 is not autoinhibited but requires Src for activation. Chan W, Sit ST, Manser E. Biochem J 435 355-364 (2011)
  17. Synthesis and optimization of substituted furo[2,3-d]-pyrimidin-4-amines and 7H-pyrrolo[2,3-d]pyrimidin-4-amines as ACK1 inhibitors. Jiao X, Kopecky DJ, Liu J, Liu J, Jaen JC, Cardozo MG, Sharma R, Walker N, Wesche H, Li S, Farrelly E, Xiao SH, Wang Z, Kayser F. Bioorg Med Chem Lett 22 6212-6217 (2012)
  18. Structure-function correlation of G6, a novel small molecule inhibitor of Jak2: indispensability of the stilbenoid core. Majumder A, Govindasamy L, Magis A, Kiss R, Polgár T, Baskin R, Allan RW, Agbandje-McKenna M, Reuther GW, Keseru GM, Bisht KS, Sayeski PP. J Biol Chem 285 31399-31407 (2010)
  19. Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1. Rudd ML, Mohamed H, Price JC, O'Hara AJ, Le Gallo M, Urick ME, NISC Comparative Sequencing Program, Cruz P, Zhang S, Hansen NF, Godwin AK, Sgroi DC, Wolfsberg TG, Mullikin JC, Merino MJ, Bell DW. BMC Cancer 14 884 (2014)
  20. Overexpression of activated Cdc42-associated kinase1 (Ack1) predicts tumor recurrence and poor survival in human hepatocellular carcinoma. Wang B, Xu T, Liu J, Zang S, Gao L, Huang A. Pathol Res Pract 210 787-792 (2014)
  21. Effect of set up protocols on the accuracy of alchemical free energy calculation over a set of ACK1 inhibitors. Granadino-Roldán JM, Mey ASJS, Pérez González JJ, Bosisio S, Rubio-Martinez J, Michel J. PLoS One 14 e0213217 (2019)
  22. Effects of ligand binding upon flexibility of proteins. Erman B. Proteins 83 805-808 (2015)
  23. Identification of novel Ack1-interacting proteins and Ack1 phosphorylated sites in mouse brain by mass spectrometry. Del Mar Masdeu M, Armendáriz BG, Torre A, Soriano E, Burgaya F, Ureña JM. Oncotarget 8 101146-101157 (2017)
  24. Biochemical Discovery, Intracellular Evaluation, and Crystallographic Characterization of Synthetic and Natural Product Adenosine 3',5'-Cyclic Monophosphate-Dependent Protein Kinase A (PKA) Inhibitors. Wilson BAP, Li N, Martinez Fiesco JA, Dalilian M, Wang D, Smith EA, Wamiru A, Shah R, Goncharova EI, Beutler JA, Grkovic T, Zhang P, O'Keefe BR. ACS Pharmacol Transl Sci 6 633-650 (2023)
  25. Phosphorylation State-Dependent High Throughput Screening of the c-Met Kinase. Behshad E, Klabe RM, Margulis A, Becker-Pasha M, Rupar MJ, Collier P, Liu PC, Hollis GF, Burn TC, Wynn R. Curr Chem Genomics 4 27-33 (2010)


Quick links